Crossover Comparison of Timolol and Latanoprost in Chronic PrimaryAngle-closure Glaucoma | Glaucoma | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Camras  CBAlm  AWatson  PStjernschantz  JLatanoprost Study Groups, Latanoprost, a prostaglandin analogue, for glaucoma treatment: efficacyand safety after 1 year of treatment in 198 patients.  Ophthalmology. 1996;1031916- 1924PubMedGoogle ScholarCrossref
2.
Watson  PGLatanoprost Study Groups, Latanoprost: two years experience of its use in the United Kingdom.  Ophthalmology. 1998;10582- 87PubMedGoogle ScholarCrossref
3.
Suzuki  MMishima  HKMasuda  KAraic  MKitazawa  YAzuma  I Efficacy and safety of latanoprost eye drops for glaucoma treatment:a 1-year study in Japan.  Jpn J Ophthalmol. 2000;4433- 38PubMedGoogle ScholarCrossref
4.
Camras  CBUnited States Latanoprost Study Groups, Comparison of latanoprost and timolol in patients with ocular hypertensionand glaucoma: a six month, masked, multicentric trial in the United States.  Ophthalmology. 1996;103138- 147PubMedGoogle ScholarCrossref
5.
Watson  PStjernschantz  JLatanoprost  Study Group A six month randomized, double-masked study comparing latanoprost withtimolol in open-angle glaucoma and ocular hypertension.  Ophthalmology. 1996;103126- 137PubMedGoogle ScholarCrossref
6.
Sihota  RLakshmaiah  NCWalia  KBSharma  SPailoor  JAgarwal  HC The trabecular meshwork in acute and chronic angle-closure glaucoma.  Indian J Ophthalmol. 2001;49255- 260PubMedGoogle Scholar
7.
Gelber  ECAnderson  DR Surgical decisions in chronic angle-closure glaucoma.  Arch Ophthalmol. 1976;941481- 1484PubMedGoogle ScholarCrossref
8.
Playfair  TJWatson  PG Management of chronic or intermittent primary angle-closure glaucoma:a long-term follow-up of the results of peripheral iridectomy used as an initialprocedure.  Br J Ophthalmol. 1979;6323- 28PubMedGoogle ScholarCrossref
9.
Steinbach  PDGruia  DG Long-term study of chronic glaucoma treated with beta blockers (timolol).  Klin Monatsbl Augenheilkd. 1987;190534- 538PubMedGoogle ScholarCrossref
10.
Sihota  RAgarwal  HC Profile of the subtypes of angle-closure glaucoma in a tertiary hospitalin India.  Indian J Ophthalmol. 1998;4625- 29PubMedGoogle Scholar
11.
Aung  TWong  HTYip  CCLeong  JYChan  YHChew  PT Comparison of the intraocular pressure lowering effect of latanoprostand timolol in patients with chronic angle-closure glaucoma: a preliminarystudy.  Ophthalmology. 2000;1071178- 1183PubMedGoogle ScholarCrossref
12.
Hedman  KAlm  A A pooled data analysis of three randomized, double-masked, six-monthclinical studies comparing the intraocular pressure reducing effect of latanoprostand timolol.  Eur J Ophthalmol. 2000;1095- 104PubMedGoogle Scholar
13.
Hovding  GAasved  H Prognostic factors in development of manifest open-angle glaucoma:a long term follow up study of hypertensive and normotensive eyes.  Acta Ophthalmol (Copenh). 1986;64601- 608PubMedGoogle ScholarCrossref
14.
Asrani  SZeimer  RWilinsky  JGieser  DVitale  SLindenmuth  K Large diurnal fluctuations in intraocular pressure are an independentrisk factor in patients of glaucoma.  J Glaucoma. 2000;9134- 142PubMedGoogle ScholarCrossref
15.
Orzalesi  NRossetti  LInvernizzi  TBottoli  AAuteitano  A Effect of timolol, latanoprost and dorzolamide on circadian intraocularpressure in glaucoma or ocular hypertension.  Invest Ophthalmol Vis Sci. 2000;412566- 2572PubMedGoogle Scholar
16.
Racz  PRuzsonyi  MRNagy  ZT  et al.  Around-the-clock (circadian) intraocular pressure reduction with once-dailyapplication of 0.005% latanoprost by itself or in combination with timolol.  Arch Ophthalmol. 1996;114268- 273PubMedGoogle ScholarCrossref
Clinical Sciences
February 2004

Crossover Comparison of Timolol and Latanoprost in Chronic PrimaryAngle-closure Glaucoma

Author Affiliations

From the Dr Rajendra Prasad Centre for Ophthalmic Sciences, All IndiaInstitute of Medical Sciences, New Delhi, India. The authors have no relevantfinancial interest in this article.

Arch Ophthalmol. 2004;122(2):185-189. doi:10.1001/archopht.122.2.185
Abstract

Objective  To compare latanoprost and timolol maleate as primary therapy in 60eyes with chronic primary angle-closure glaucoma after a laser iridotomy.

Methods  We performed a prospective, randomized, crossover study of 60 eyes of30 patients with chronic primary angle-closure glaucoma after laser iridotomy.Patients were randomized to 2 groups: those taking latanoprost once dailyor those taking timolol twice daily. Three months after treatment with thefirst drug, the second drug was substituted. The circadian rhythm of intraocularpressure (IOP) was recorded before the start of therapy, at 3 months, andat 7 months. The fourth month was the washout period for the first drug.

Results  The mean baseline IOP was 23.5 ± 2.1 mm Hg, which decreased by8.2 ± 2.0 mm Hg with latanoprost (P<.001)and by 6.1 ± 1.7 mm Hg with timolol (P = .01).The decrease in IOP was greater for patients taking latanoprost (P<.001). Latanoprost was significantly more effective in eyes havingmorning and afternoon peaks of IOP. A total of 43 eyes (72%) of patients takinglatanoprost and 26 (43%) on timolol achieved a reduction of more than 30%from baseline IOP.

Conclusion  There were greater mean and peak IOP reductions achieved with 0.005%latanoprost once daily compared with 0.5% timolol twice daily.

×